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Background: The prevalence of Restless legs syndrome (RLS) in End Stage Renal Disease (ESRD) patients is higher
than that in the general population. However, the associations of RLS within the ESRD population are inconsistent
and RLS is usually neglected in dialysis centers, although it impairs the life quality among ESRD patients. We aim to
investigate the prevalence of RLS in patients with ESRD undergoing maintenance hemodialysis and evaluate the
risk factors of developing RLS and the effect of RLS on quality of life among ESRD patients.
Methods: ESRD patients undergoing maintenance hemodialysis in Shanghai General Hospital dialysis unit from July
2016 to October 2016 were enrolled in the study. RLS was diagnosed according to the criteria of the International
Restless Legs Syndrome Study Group (IRLSSG). IRLSSG Severity Scale was used to evaluate the severity of RLS. Pittsburgh
Sleep Quality Index (PSQI) was used to evaluate sleep quality, and Hospital Anxiety and Depression Scale (HADS) was
used to estimate anxiety and depression. Serologic and historic variables were analyzed to determine predictors of RLS in
the ESRD population.
Results: A total of 137 ESRD patients were enrolled. The prevalence of RLS among the ESRD patients was 20.44%. The risk
of RLS was increased significantly in females (OR = 2.729, p = 0.032) and daily alcohol drinkers (OR = 4.716, p = 0.022). RLS
increased the risks of sleep disorders (25/28, 89.3% vs 73/109, 67.0%, p = 0.02) and sedative hypnotics intake (7/28, 25.0%
vs 10/109, 9.2%, p = 0.047) and impaired the sleep quality (7/109 vs 11/28, p = 0.001) according to PSQI sum scores.
Conclusion: A high RLS prevalence among the ESRD patients undergoing hemodialysis was confirmed. ESRD patients
who are women and drinking alcohol have a higher risk of RLS. The sleep quality was significantly impaired and sleeping
medication use was more common among the ESRD patients with RLS.
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Restless legs syndrome (RLS) is a common neurological
disorder, which can be primary or associated with other
conditions. RLS symptoms are characterized by the un-
comfortable or abnormal sensations inside the legs or
arms, associated with an urge to move the limbs. The
symptoms usually occur at rest and at night, and can be
temporarily relieved by movement [1]. RLS has an* Correspondence: yuqingsl0618@163.com; yunchw@medmail.com.cn
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with mood disorders such as anxiety and depression [2].
In the general population, the prevalence of RLS
ranges from 3 to 9%, depending on the age and gender
[3]. However, the prevalence of RLS in End Stage Renal
Disease (ESRD) characterized as permanent loss of renal
function requiring renal replacement therapy or dialysis,
is 6.6–70%, which is much higher than the general popu-
lation [4].
RLS in ESRD patients has been variably reported to be
associated with female gender [5, 6], duration of dialysis
[4, 7], diabetes mellitus [4, 8–10], iron deficiency anemia
[4, 10, 11], parathyroid hormone [12], increased body
mass index (BMI) [13], and increased homocysteine
[14]. However, results are very inconsistent. [10, 15].le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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pairs quality of life compared with the ESRD patients
without RLS, possibly due to the poor sleep quality, in-
somnia or depression [9, 16]. Therefore, further studies
are needed to determine the prevalence, risk factors and
impact of RLS in ESRD patients.
The aim of the study was to investigate the prevalence
of RLS in patients with ESRD undergoing maintenance
hemodialysis in Shanghai General Hospital, China. We
also aimed to evaluate the risk factors of developing RLS
and to investigate the effect of RLS on quality of life
among ESRD patients.Methods
Study subjects
All ESRD patients undergoing long-term hemodialysis in
the Shanghai General Hospital dialysis unit from July
2016 to October 2016 were approached for our study.
Patients will be excluded when they were less than 3
months with hemodialysis duration, less than 18 years
old, pregnant, Parkinson’s disease, type 1 diabetes melli-
tus and peripheral neuropathy. The protocol was ap-
proved by the ethics committee of Shanghai General
Hospital, and written informed consents were obtained.Study design
Of the 161 ESRD patients enrolled in our study, 24 pa-
tients were excluded, including two patients with the less
than 3 months of hemodialysis duration, twenty-one pa-
tients declined to participate, and one patient had type 1
diabetes mellitus, leaving 137 patients.
All the patients are diagnosed with the detailed history
and International Restless Legs Syndrome Study Group
(IRLSSG) scale which were carried out by neurologists
through face-to-face interviews. The demographic ques-
tionnaire included gender, age, height, weight, cause of
ESRD, hemodialysis data, other diseases, medication his-
tory, family history, personal history, etc. Furthermore,
every participant was requested to complete the Pitts-
burgh Sleep Quality Index (PSQI) and Hospital Anxiety
and Depression Scale (HADS).
The PSQI is used to evaluate the sleep quality of ESRD
patients in seven parts: subjective quality of sleep, sleep
latency, sleep duration, habitual sleep efficiency, pres-
ence of sleep disturbances, use of hypnotic-sedative
medication and daytime dysfunction [17]. Participants
with PSQI total scores of ≥5 were considered to have
sleep disorders in our study.
The HADS consists of two subscales (HADS-A and
HADS-D), which are composed of seven anxiety items
and seven depression items respectively. The four op-
tions of every item were scored 0–3. The total subscale
scores of 8–10 indicate doubtful anxiety or depressionand sores of 11 or more indicate definite anxiety or
depression [18].
The presence of RLS was assessed using the minimum
diagnostic criteria recommended by the International
Restless Legs Syndrome Study Group (IRLSSG), which
consists of four questions: (1) an urge to move the legs,
usually accompanied or caused by uncomfortable and
unpleasant sensations in the legs; (2) the urge to move
or unpleasant sensations begin or worsen during periods
of rest or inactivity, such as lying or sitting; (3) the urge
to move or unpleasant sensations are partially or totally
relieved by movement, such as walking or stretching, at
least as long as the activity continues, and (4) the urge
to move or unpleasant sensations are worse in the even-
ing or night than during the day or only occur in the
evening or night [1]. Participants with four “yes” replied
to the four aforementioned questions were diagnosed
with RLS. RLS participants completed the IRLSSG Se-
verity Scale with 10 questions for evaluating severity of
the RLS symptoms [19]. Patients were classified into
four groups with mild (0–10 scores), moderate (11–20
scores), severe (21–30 scores) and very severe (31–40
scores) RLS.
Laboratory blood tests included blood urea nitrogen
(BUN), pre-dialysis creatinine, post-dialysis creatinine,
albumin, alkaline phosphatase (AKP), calcium, phosphate,
hemoglobin, serum iron, ferritin, transferrin, total iron
binding capacity (TIBC) and parathyroid hormone (PTH),
which were tested within a week of the interview.
Statistical analysis
The data were analyzed via SPSS version 17.0 (SPSS Inc.,
Chicago, IL, USA). T-test or Mann-Whitney U test was
used for continuous variables and Chi-square test was
used for categorical variables. The continuous data are
presented as mean and standard deviation (normal dis-
tribution) or median and quartiles (non-normal distribu-
tion). Multivariate analysis was performed by binary
logistic regression analysis, which allows adjustment for
confounding factors, and all variables that had p < 0.1 in
univariate analysis were used as independent variables.
p < 0.05 was considered statistically significant.Results
The data of 137 patients were analyzed in our study.
There were 74 males (54%) and 63 females (46%). The
mean age was 55.47 ± 12.76 years old. The mean duration
of hemodialysis was 98.35 ± 71.66months. The causes of
ESRD included chronic glomerulonephritis (n = 89,
65.0%), hypertensive nephrosclerosis (n = 17, 12.4%), dia-
betic nephropathy (n = 6, 4.4%), polycystic kidney disease
(n = 8, 5.8%), drug induced nephropathy (n = 5, 3.6%), vas-
cular kidney disease (n = 6, 4.4%), autoimmune nephritis
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found in 28 patients (20.44%). Only one of them had been
previously diagnosed with RLS and received pramipexole
treatment. There were 6 patients with mild RLS, 15 pa-
tients with moderate RLS, 7 patients with severe RLS and
no patients with very severe RLS, based on the IRLSSG
rating scale.
Demographic data and routine laboratory blood test
data are summarized in Table 1 and Table 2. According
to the univariate analyses, BUN (p = 0.014) and serum
iron (p = 0.034) were significantly higher in RLS positive
group. Female sex (p = 0.08), post-dialysis systolic pressure
(p = 0.053) and alcohol intake (p = 0.069) seems to be the
risk factors of RLS, but without statistically significance.
Age, body mass index (BMI), weeks on hemodialysis, fre-




Educational Attainment < Middle school
Middle school or vocationa
High school or higher




Duration of Hemodialysis (week)
Frequency of Hemodialysis 3 times/week
Dialysis Solution Temperature 36 °C
36.5 °C
37 °C
Pre-dialysis Systolic Pressure (mmHg)
Pre-dialysis Diastolic Pressure (mmHg)
Post-dialysis Systolic Pressure (mmHg)







Smoking Daily and regularly
Alcohol intake Daily and regularly
Tea intake Daily and regularly
Coffee intake Daily and regularly
Abbreviations: ESRD end stage renal disease, RLS restless legs syndrome, RLS- withoudiabetes mellitus Type 2, family history of RLS, smoking,
tea intake, coffee intake and other routine laboratory
blood test data including creatinine, albumin, alkaline
phosphatase (AKP), calcium, phosphate, hemoglobin, fer-
ritin, transferrin, total iron binding capacity (TIBC), para-
thyroid hormone (PTH), URR, and Kt/v, showed no
relationship with RLS (P Value > 0.05).
All variables that had p < 0.1 in univariate analysis, in-
cluding BUN (p = 0.014), serum iron (p = 0.034), female
(p = 0.08), post-dialysis systolic pressure (p = 0.053) and
alcohol intake (p = 0.069), were included in multivariable
regression analysis to identify independent risk factors of
RLS among ESRD patients. We found that only female
sex (OR 2.729, 95% CI 1.087–6.849, p = 0.032) and daily
alcohol intake (OR 4.716, 95% CI 1.247–17.837, p = 0.022)
were significantly independent risk factors.ut RLS
Patients with ESRD, N (%)
RLS –(n = 109) RLS +(n = 28) p value
46 (42.2%) 17 (58.8%) 0.08
55.83 ± 13.20 54.04 ± 10.40 0.505
7 (6.4%) 4 (23.5%)
l 70 (64.2%) 16 (57.1%)
32 (29.4%) 8 (28.6%) 0.548
18 (16.5%) 6 (21.4%)
67 (61.5%) 18 (64.3%)
20 (18.3%) 3 (10.7%)
4 (3.7%) 1 (3.6%) 0.346
90 (25-132) 113.5 (39-159.75) 0.224
102 (93.6%) 25 (89.3%) 0.438
52 (47.7%) 14 (50.0%)
46 (42.2%) 10 (35.7%)
11 (10.1%) 4 (15.3%) 0.991
131.51 ± 20.44 125.36 ± 21.21 0.161
78.97 ± 11.46 77.86 ± 12.80 0.655
122.89 ± 19.88 115 ± 15.46 0.053
74.60 ± 11.71 72.32 ± 11.43 0.358
28 (25.7%) 9 (32.1%) 0.734
89 (81.7%) 24 (86.0%) 0.783
94 (86.2%) 22 (78.6%)
10 (9.2%) 3 (10.7%)
2 (1.8%) 3 (10.7%)
3 (2.8%) 0 (0%) 0.151
28 (25.7%) 9 (32.1%) 0.493
7 (6.4%) 5 (17.9%) 0.069
43 (39.4%) 9 (32.1%) 0.477
18 (16.5%) 6 (21.4%) 0.58
t RLS, RLS+ with RLS, BMI body mass index
Table 3 Sleep quality, depression, anxiety and medications
between RLS- and RLS+
Patients with ESRD, N (%)
RLS- (n = 109) RLS+ (n = 28) P- value
PSQI 7 (4-10) 11 (5.25-13) 0.001
Sleep disorder 73 (67.0%) 25 (89.3%) 0.020
HADS-D 5 (1-9) 3 (1-7) 0.622
Depression No symptom 70 (64.2%) 22 (78.6%) 0.251
Suspicious 20 (18.3%) 1 (3.6%)
Confirmed 19 (17.4%) 5 (17.9%)
HADS-A 2 (0-4) 3 (1-6.5) 0.151
Anxiety No symptom 99 (91%) 25 (89.3%) 0.773
Suspicious 6 (5.5%) 1 (3.6%)
Confirmed 4 (3.7%) 2 (7.1%)
Medications Anti-anemia
Medicine
85 (78.0%) 23 (82.1%) 0.631
Sedative
hypnotics
10 (9.2%) 7 (25.0%) 0.047
Abbreviations: ESRD end stage renal disease, RLS restless legs syndrome, RLS-
without RLS, RLS+ with RLS, PSQI Pittsburgh Sleep Quality Index, HADS-D
Hospital Anxiety and Depression Scale of Depression, HADS-A HADS-Anxiety
Table 2 Laboratory blood test of the ESRD patients with and
without RLS
Patients with ESRD, N (%)
Variables RLS – (n = 109) RLS + (n = 28) p value
Blood Urea
Nitrogen
mmol/L 27.48 (23.31-31.35) 29.33 (27.3-34.2) 0.014
Pre-dialysis
Creatinine
mg/dl 1037 (874.5-1204.5) 1053 (900-1193.5) 0.852
Pro-dialysis
Creatinine
mg/dl 350 (276-418) 327 (247-462) 0.378
D-value of
Creatinine
mg/dl 685 (559.5-791.5) 699 (641.25-805.75) 0.370
Calcium mg/dL 2.31 ± 0.26 2.32 ± 0.26 0.744
Phosphorus mg/dL 1.90 ± 0.47 2.11 ± 0.70 0.155
Ca*P
product
mg2/dL2 4.41 ± 1.30 4.92 ± 1.75 0.157
Albumin g/dL 39.24 ± 4.24 39.70 ± 6.29 0.650
Alkaline
Phosphatase
U/L 73 (54-93.5) 75 (61-98.75) 0.523
Hemoglobin g/L 100.13 ± 15.54 105.43 ± 22.1 0.240
Serum Iron μmol/L 13.2 (9.45-16.3) 15.41 (12.5-18.0) 0.034
Ferritin μg/L 194 (68.85-335.3) 122.5 (53.8-232.99) 0.371
Transferrin g/L 2.11 (1.83-2.36) 2.14 (1.78-2.45) 0.953
TIBC μmol/L 47.02 ± 8.49 48.51 ± 9.67 0.424
Parathyroid
Hormone
pg/mL 203.9 (65.91-472.1) 258.3 (62.95-574.1) 0.522
Kt/V 1.53 ± 0.61 1.49 ± 0.34 0.783
URR % 70.19 ± 8.15 70.27 ± 8.05 0.967
Abbreviations: ESRD end stage renal disease, RLS restless legs syndrome, RLS-
without RLS, RLS+ with RLS, Ca*P product calcium phosphorus product, TIBC
total iron-binding capacity, Kt/V is a number used to quantify hemodialysis
(K, dialyzer clearance of urea; t, dialysis time; V, volume of distribution of urea,
approximately equal to patient’s total body water); URR, urea reduction ratio
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medications between ESRD patients with RLS and those
without RLS (Table 3). RLS patients had significantly higher
proportion of sleep disorders (89.3% vs 67.0%, p = 0.02) and
lower sleep quality (11 vs 7, p = 0.001) according to PSQI
total scores. The proportion of sedative hypnotics intake
(25.0% vs 9.2%, p = 0.047) was significantly increased in the
patients with RLS.
Discussion
The prevalence of RLS among the ESRD patients varies
widely in different studies. It was 15.8% in Iran, 22% in
Japan, 25.3% in Taiwan, 26.6% in Greek, and 52.6% in
Brazil [4, 5, 7, 20, 21]. However, it has not been studied
about the prevalence in mainland China. The discrepancy
of RLS prevalence among ESRD patients might be influ-
enced by racial heterogeneity, demographic difference
[10], diagnostic criteria of RLS [22], differences in dialysis
techniques, and methods of study. In our study, all the
patients were long-term residence in Shanghai of China.RLS diagnosis was made according to the 4 minimum
diagnostic criteria of IRLSSG. Our prevalence of RLS
among ESRD patients (20.44%) was similar to some large
scale studies [4, 5, 10] and significantly higher than among
the general Chinese population (7.2%) [23].
Our result reveals that RLS is more common in female
ESRD patients (OR = 2.729, p = 0.032), similar to some
other studies [5, 8, 24]. In general population studies,
RLS is consistently more common in females [23, 25],
although one German study found this was explained by
previous pregnancies, such that null-parous women had
similar RLS rates as men [25, 26]. The high level of estro-
gen during pregnancy could trigger RLS [27]. Interest-
ingly, the concentration of estrogen level is usually high in
advanced kidney failure, potentially explaining this [28].
In our study, the ratio of alcohol intake among RLS
patients was higher than patients without RLS, which
was not significant (p = 0.069) in univariate analysis but
was significant (p = 0.022) in the multivariable backward
logistic regression model. Regular alcohol intake in-
creased the risk of developing RLS by 4.72 times in our
ESRD patients. One study demonstrated that alcohol in-
take raised the risk of developing RLS in the general
population [29]. However, a potentially protective effect
of alcohol on the risk of RLS was found in several stud-
ies [30, 31]. These contradictory conclusions can be ar-
gued that moderate drinking could reduce the risk of
RLS while excessive alcohol consumption could produce
and aggravate RLS symptoms [32]. Therefore, additional
studies are needed to clarify the role of alcohol in ESRD
patients with RLS.
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significant association between diabetes mellitus type 2
and RLS among ESRD patients. It is not clear whether
diabetes mellitus itself or diabetic peripheral neuropathy
is the dominant risk factor [33]. Some other studies
found that there are no correlationship between diabetes
mellitus and the occurrence of RLS in ESRD patients
[34, 35]. While a multicenter study in Taiwan showed
that having type 2 diabetes is associated with RLS [4].
No significant association was found between iron defi-
ciency and anemia, or iron deficiency and RLS among
ESRD patients in our study. Iron-Deficiency Anemia
(IDA) and the relevant blood parameters were reported as
significant risk factors of RLS among the patients with
ESRD [4, 10, 11]. Furthermore, the symptoms of RLS have
improved with high-dose iron dextran therapy among the
ESRD patients, which also suggested that IDA could
induce RLS [36] . Other studies showed no relationship
between IDA and RLS in ESRD patients [5, 8, 12].
In our study, we didn’t find any difference between
two groups regarding to Parathyroid hormone (PTH).
Previous studies show mixed results. One previous study
found PTH levels to be lower in the ESRD patients with
RLS than those without RLS [12]. On the contrary, re-
cent studies indicated that PTH was an independent risk
factor [5, 37], which is supported by the finding that
parathyroidectomy improved RLS in ESRD patients in
one study [20]. Nevertheless, some studies suggested
that there is no association between PTH and RLS in
the ESRD patients [4, 10, 14]. Therefore, further large
studies are needed to clarify the relationship between
PTH and RLS in ESRD patients.
In our study, we found no statistical difference of BMI
between ESRD patients with RLS and those without RLS
(p = 0.346), which was similar to some other studies of RLS
among patient with ESRD. In contrast to the results of our
study, some studies indicated that the increasing BMI led
to significantly higher odds of developing RLS both in
patients with ESRD and in general population [30, 38].
Our study found no significant association between RLS
and the duration of hemodialysis, blood pressure on
hemodialysis, smoking, tea or coffee intake and blood
markers in multivariable backward logistic regression ana-
lysis, similar to some previous studies [10, 15, 34, 38].
Previous studies indicated that ESRD patients with
RLS suffered from poorer sleep quality than those with-
out RLS [4, 14, 39]. Our study also found significant
associations between RLS and sleep-related problems,
including prolonged sleep latency, night awakening,
shorten sleep duration and sleeping medication use. And
also, RLS had an association with impairment of sleep
quality among the ESRD patients. Sleep disorders
occurred more frequently and sleep quality was poorer
among ESRD patients with RLS than those without RLS.Moreover, ESRD patients with RLS were more likely to
require sedative hypnotics to improve their sleep quality.
Depression prevalence in hemodialysis patients was re-
ported to be 15–30%, depending on the method of depres-
sion assessment and demographics [40]. The incidence of
anxiety in hemodialysis patients ranged from 12 to 52%
[41]. In our study, the incidence of confirmed depression in
ESRD patients with RLS of 17.4% was similar to the previ-
ous studies. However, there was no significant difference in
depression between ESRD patients with RLS and without
RLS. The incidence of confirmed anxiety in ESRD patients
with RLS (7.1%) in our study was lower than those in other
studies, and no significant difference of anxiety existed be-
tween ESRD patients with RLS and without RLS. Due to
the face-to-face interviews in the public area, patients were
likely to have misgivings about giving the real answers to
the HADS questionnaire. This may be responsible for the
irrelevancy between RLS and depression/anxiety.
Several limitations of this study should be noted. Firstly,
the cross-sectional design and descriptive nature do not
allow for conclusions about the direction of theses rela-
tionships. Secondly, this is a single-center study with com-
paratively small number of participants, which decreases
the statistical power. Thirdly, we didn’t make formal eval-
uations to look for peripheral neuropathy. Lastly, in our
present study, we only included hemodialysis patients and
did not include peritoneal dialysis patients, which partially
limits the comparison with previous studies.
Conclusion
Our study confirmed a high incidence of RLS among the
ESRD patients undergoing maintenance hemodialysis.
Among ESRD patients, the risk of RLS was significantly
increased in females and alcohol users. The sleep quality
was significantly impaired and sleeping medication use
was more frequent among the ESRD patients with RLS.
High prevalence of RLS among ESRD patients suggests
the need for clinicians to improve awareness and recog-
nition of RLS among ESRD patients. Although the risk
factors of RLS among ESRD patients were identified by
many studies, the results are still disputable. Therefore,
more multicenter studies are needed to confirm the
various risk or protective factors in the future.
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